Table 1.
Baseline demographic, clinical, and pathological characteristics.
| Variables | Patients (n = 308) |
|---|---|
| Age (years) | 51.4 ± 9.7 |
| Gender (male) | 214 (69.5) |
| Duration of diabetes (months) | 97.8 ± 70.3 |
| Diabetic retinopathy (%) | 138 (44.8) |
| Body mass index (kg/m2) | 25.78 ± 3.78 |
| Hypertension (%) | 265 (86.0) |
| Systolic blood pressure (mmHg) | 145 ± 23 |
| Diastolic blood pressure (mmHg) | 86 ± 13 |
| HbA1C (%) | 7.3 (6.3-8.5) |
| Initial proteinuria (g/24 h) | 4.3 (2.0-7.8) |
| Serum creatinine (μmol/L) | 130 ± 65 |
| Cystatin C (mg/L) | 1.61 ± 0.60 |
| Triglyceride (mmol/L) | 2.19 ± 1.80 |
| Total cholesterol (mmol/L) | 5.22 ± 1.60 |
| Thyroid-stimulating hormone (mU/L) | 3.15 (1.96-5.60) (n = 155) |
| Free triiodothyronine 3 (pmol/L) | 3.92 (3.39-4.41) (n = 151) |
| Free triiodothyronine 4 (pmol/L) | 14.95 (13.17-16.61) (n = 154) |
| eGFRCKD-EPI-Cr | 62.6 ± 28.7 |
| eGFRCKD-EPI-CysC | 50.3 ± 23.3 |
| eGFRCKD-EPI-Cr-CysC | 54.6 ± 24.9 |
| RAAS inhibitors (%) | 251 (81.5) |
| Insulin therapy (%) | 222 (72.1) |
| Statins (%) | 177 (57.5) |
| Glomerular class | |
| I | 17 |
| IIa | 75 |
| IIb | 29 |
| III | 140 |
| IV | 47 |
| Interstitial fibrosis and tubular atrophy | |
| 0 | 10 |
| 1 | 138 |
| 2 | 127 |
| 3 | 33 |
| Interstitial inflammation | |
| 0 | 20 |
| 1 | 233 |
| 2 | 55 |
| Arteriolar hyalinosis | |
| 0 | 34 |
| 1 | 162 |
| 2 | 112 |
| Reach end-stage kidney disease | 131 |
| Median kidney survival time (months) | 20 (13-33) |
Data are presented as the mean ± standard and the median with range or counts and percentages.